SNAPS Breast Cancer Patient Study Breast Cancer Patients
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorImmunis.AI
About this trial
Differential immunogenomic signatures from peripheral blood CD14 (phagocytic) and CD2 (non-phagocytic) cells have been associated with multiple cancers and disease states. In particular several large clinical studies at Immunis.AI have demonstrated robust immunogenomic signatures in early-stage prostate cancer. Immunis.AI therefore hypothesizes that a peripheral blood immunogenomic signature will identify patients with various stages of breast cancer from healthy negative controls.
Eligibility criteria
Qualifiers
Patients > 18 yrs of age.
Patients diagnosed with stage I-IV breast cancer, who have not begun definitive therapy.
Patients undergoing screening mammograms for breast cancer.
Disqualifiers
Patients with a history of a different cancer within the previous 3 years (except non melanoma skin cancer).
Any prior treatment (surgery, chemo, hormonal, radiation, biologics, etc.) for current cancer.
Any biopsy which resulted in the entire tumor tissue being removed.
History of previous breast cancer.
Trial design
Treatments tested in this trial
- Blood test
Treatment groups
500 Participants
are divided into 2 treatment groupsSponsors and collaborators
Immunis.AI
Lead sponsor
Duke University
Collaborator
Source ClinicalTrials.gov